In vivo magnetic resonance spectroscopy

Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates

Retrieved on: 
Friday, November 3, 2023

The remaining 13% interest in these potential future milestone payments and royalties was acquired by Ligand in October 2023.

Key Points: 
  • The remaining 13% interest in these potential future milestone payments and royalties was acquired by Ligand in October 2023.
  • General and administrative expenses were $6.8 million for the three months ended September 30, 2023, as compared to $7.6 million for the same period in 2022.
  • The decrease reflects the impact of headcount reductions conducted as part of organizational changes made in the first half of 2023.
  • Total operating expenses were $12.1 million for the three months ended September 30, 2023, as compared to $12.8 million for the same period last year.

UPDATE | Advanced imaging reveals altered brain chemistry of babies with congenital heart disease

Retrieved on: 
Monday, October 9, 2023

They found:

Key Points: 
  • They found:
    Those with CHD had higher levels of choline and lower levels of N-Acetyl aspartate-to-choline ratios compared to healthy babies, potentially representing disrupted brain development.
  • Babies with more complex CHD also had higher levels of cerebral lactate compared to babies with two ventricle CHD.
  • These critical heart defects generally require babies to undergo heart surgery not long after birth.
  • , chief of the Advanced Technologies and Surgery Branch in the Division of Cardiovascular Sciences at the National Heart, Lung and Blood Institute.

Advanced imaging reveals altered brain chemistry of babies with congenital heart disease

Retrieved on: 
Monday, October 9, 2023

They found:

Key Points: 
  • They found:
    Those with CHD had higher levels of choline and lower levels of N-Acetyl aspartate-to-choline ratios compared to healthy babies, potentially representing disrupted brain development.
  • Babies with more complex CHD also had higher levels of cerebral lactate compared to babies with two ventricle CHD.
  • These critical heart defects generally require babies to undergo heart surgery not long after birth.
  • , chief of the Advanced Technologies and Surgery Branch in the Division of Cardiovascular Sciences at the National Heart, Lung and Blood Institute.

Alterity Therapeutics Presents New Data on Multiple System Atrophy, a Rare Parkinsonian Disorder

Retrieved on: 
Thursday, August 31, 2023

MELBOURNE, Australia and SAN FRANCISCO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that presentations from its bioMUSE natural history study of Multiple System Atrophy (MSA) were delivered at the International Congress of Parkinson’s Disease and Movement Disorders (MDS) taking place August 27 - 31, 2023 in Copenhagen, Denmark.

Key Points: 
  • The posters presented from Alterity’s bioMUSE study address the need for incorporating biomarkers as a critical component for diagnosis of MSA.
  • The diagnosis of early MSA can be challenging as individuals often present similarly to Parkinson’s disease (PD).
  • In contrast to PD, MSA is rapidly progressive and, therefore, it is vital to accurately diagnose patients enrolling in clinical trials.
  • The poster entitled, “A multimodal approach for diagnosis of early Multiple System Atrophy” was presented by Dr. Claassen.

BioVie Presents Data Showing How NE3107 May Potentially Regulate DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease

Retrieved on: 
Monday, July 17, 2023

Treatment with NE3107 led to >50% reductions in DNA methylation of 400 CpGs* and some in a manner that was significantly correlated to observed clinical improvements in cognition and various biomarkers.

Key Points: 
  • Treatment with NE3107 led to >50% reductions in DNA methylation of 400 CpGs* and some in a manner that was significantly correlated to observed clinical improvements in cognition and various biomarkers.
  • Over 3,000 significant correlations were found linking reductions in DNA methylation of various CpGs and cognitive, biomarker and neuroimaging endpoints.
  • The poster was presented yesterday at the Alzheimer’s Associate’s International Conference (AAIC) held in Amsterdam July 16-20, 2023.
  • The new data that was presented details how NE3107 may potentially change or affect the degree of methylation of specific genes that are correlated with various markers of disease.

People with obsessive-compulsive disorder have an imbalance of brain chemicals – our discovery could mean a treatment breakthrough

Retrieved on: 
Wednesday, June 28, 2023

But OCD is actually a severe and disabling disorder characterised by obsessions – recurrent intrusive thoughts, impulses or images that are unwanted and anxiety provoking.

Key Points: 
  • But OCD is actually a severe and disabling disorder characterised by obsessions – recurrent intrusive thoughts, impulses or images that are unwanted and anxiety provoking.
  • Some people with OCD are engaged in rituals for much of their waking life and cannot even leave their homes.
  • But in our new research, published in Nature Communications, we discovered an imbalance in brain chemicals in OCD that could lead to radically different and improved treatments.
  • Scientists have suspected that this involves an imbalance between chemical messengers, or neurotransmitters, called
    glutamate and gamma-aminobutyric acid (Gaba) in certain brain regions.

Magnetic resonance spectroscopy

    • To study glutamate and Gaba, we used a high-strength magnet (called 7-Tesla) to perform magnetic resonance spectroscopy.
    • This helps scientists to measure what kind of chemicals exist there – and their concentration.
    • This allowed us to detect and measure glutamate and Gaba levels separately in different brain regions.
    • Importantly, the clinical severity of compulsive symptoms of OCD correlated with the glutamate levels we measured in the SMA.

Future treatments

    • The finding raises hopes for better treatments for OCD, focusing on re-balancing glutamate and Gaba levels in key brain regions.
    • In patients with extremely severe OCD, for whom all other usual treatments have failed, surgeons have actually removed the ACC.
    • And for less severely impaired patients where such drastic treatments are not justified, there may be therapeutic possibilities of using “transcranial magnetic stimulation”.
    • In future, if OCD is diagnosed early in the course of the illness – and the chemical imbalance we have discovered is also detected – then these new treatments offer hope for improved quality of life and wellbeing for patients the disorder.

BridgeBio Pharma Presents Updated Encouraging Clinical and Biomarker Data from its BBP-812 Canavan Disease Gene Therapy Program at the 2023 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

Retrieved on: 
Monday, May 22, 2023

“Canavan disease is a rapidly progressive, rare neurological disease that affects children from birth and has no treatment options beyond supportive care.

Key Points: 
  • “Canavan disease is a rapidly progressive, rare neurological disease that affects children from birth and has no treatment options beyond supportive care.
  • The changes in key biomarkers, brain myelination and – critically – clinical function observed in children receiving BBP-812 in our study are compelling, and as we continue to advance our program we are hopeful that we will see outcomes that make a meaningful difference in the lives of children with Canavan disease and their families,” said Genevieve Laforet, M.D., Ph.D., vice president of clinical development at Aspa Therapeutics, the BridgeBio affiliate that is developing BBP-812 for Canavan disease.
  • “We are beyond grateful to the children and their families who are participating in CANaspire as well as the study investigators, who together are making it possible to explore the potential of BBP-812 as a therapy for Canavan disease.
  • Across individual participants, percent decreases in NAA from baseline ranged between 70% and 95% in cerebrospinal fluid (CSF), 29% and 88% in urine, and 8% and 75% in brain (by magnetic resonance spectroscopy)
    All participants in the CANaspire trial had urine NAA levels consistent with typical Canavan disease prior to receiving BBP-812.

Myrtelle Announces Positive 6-month Post-Treatment Data in Patients in Its First-in-Human Clinical Study of rAAV-Olig001-ASPA Gene Therapy in Canavan Disease

Retrieved on: 
Wednesday, April 19, 2023

In several domains, the observed improvement in treated patients are in contrast to the observed deterioration in untreated age-matched CD patients within Myrtelle’s natural history data set.

Key Points: 
  • In several domains, the observed improvement in treated patients are in contrast to the observed deterioration in untreated age-matched CD patients within Myrtelle’s natural history data set.
  • In CD, normal brain development is impaired due to a mutation in the ASPA gene that encodes the enzyme Aspartoacylase (ASPA).
  • The oligodendrocyte-targeting rAAV vector-based gene therapy is intended to restore ASPA function and hence the metabolism of NAA and brain development in patients with CD.
  • In addition, volumetric MRI (magnetic resonance imaging) measurements showed increases in multiple brain tissue compartments and reductions in CSF volume.

HMRI Celebrates Women’s History Month: ‘Women have been at the forefront of our most groundbreaking research for decades’

Retrieved on: 
Monday, March 20, 2023

Women are and have been at the forefront of our most groundbreaking research for decades.

Key Points: 
  • Women are and have been at the forefront of our most groundbreaking research for decades.
  • Dr. Marylou Ingram, one of the most influential women scientists at HMRI, was a senior research scientist when she arrived in 1982.
  • Through a bequest, Ingram endowed the Marylou Ingram Chair in Medical Science Research, ensuring future HMRI researchers would have the resources to be as groundbreaking as she was.
  • Dr. Julia Bradsher is a successful scientist, strategic leader and the dynamic CEO of HMRI, directing the institute in its focused growth strategy.

Aclarion Adds to Strong Patent Portfolio with Notice of Allowance for New U.S. Patent Application Addressing Key Pain Indicator Biomarker

Retrieved on: 
Thursday, December 1, 2022

Broomfield, CO, Dec. 01, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it has received a Notice of Allowance for its US Patent Application 16/224,590 titled “Magnetic Resonance Spectroscopy System and Method for Diagnosing Pain or Infection Associated with Propionic Acid”. 

Key Points: 
  • Conventional imaging (lumbar MRI) for Chronic Low Back Pain offers important structural information but struggles to identify the actual source of pain.
  • Aclarions Nociscan solutionisthe first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine.
  • Biomarker data is entered into proprietary algorithms to highlight if a disc may be a source of pain.
  • This information may prove critical in supporting the optimal treatment of low back pain when infection is the underlying cause of pain.